Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $43.2 million.

  • Agios Pharmaceuticals' Prepaid Assets rose 827.63% to $43.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.2 million, marking a year-over-year increase of 827.63%. This contributed to the annual value of $40.2 million for FY2024, which is 1468.83% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Prepaid Assets of $43.2 million as of Q3 2025, which was up 827.63% from $44.7 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Prepaid Assets peaked at $46.5 million during Q3 2022, and registered a low of $19.5 million during Q1 2021.
  • Its 5-year average for Prepaid Assets is $37.8 million, with a median of $39.3 million in 2023.
  • Over the last 5 years, Agios Pharmaceuticals' Prepaid Assets had its largest YoY gain of 15070.8% in 2021, and its largest YoY loss of 3307.15% in 2021.
  • Over the past 5 years, Agios Pharmaceuticals' Prepaid Assets (Quarter) stood at $39.8 million in 2021, then fell by 2.21% to $39.0 million in 2022, then dropped by 10.1% to $35.0 million in 2023, then grew by 14.69% to $40.2 million in 2024, then rose by 7.52% to $43.2 million in 2025.
  • Its Prepaid Assets stands at $43.2 million for Q3 2025, versus $44.7 million for Q2 2025 and $42.3 million for Q1 2025.